Published in Surgery on December 01, 2007
Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg (2009) 0.99
Surgeon-performed ultrasound in patients referred for thyroid disease improves patient care by minimizing performance of unnecessary procedures and optimizing surgical treatment. World J Surg (2010) 0.80
Same-day ultrasound guidance in reoperations for locally recurrent papillary thyroid cancer. Surgery (2007) 0.80
The relevance of preoperative ultrasound cervical mapping in patients with thyroid cancer. Can J Surg (2016) 0.75
Ultrasound dye-assisted surgery (USDAS): a promising diagnostic and therapeutic tool for the treatment of cancer recurrences in the neck. Acta Otorhinolaryngol Ital (2011) 0.75
Operative bed recurrence of thyroid cancer: utility of a preoperative needle localization technique. Gland Surg (2016) 0.75
On-site ultrasound-guided localization for impalpable nodal recurrences in papillary thyroid carcinoma patients. J Korean Surg Soc (2013) 0.75
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
Thyroid nodules (≥4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg (2014) 2.40
Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. AJR Am J Roentgenol (2007) 2.27
MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol (2011) 2.25
The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery (2007) 2.04
BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2012) 1.90
Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid (2009) 1.90
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery (2009) 1.72
Current safety practices relating to I-131 administration for diseases of the thyroid: a survey of physicians and allied practitioners. Thyroid (2011) 1.51
The small abnormal parathyroid gland is increasingly common and heralds operative complexity. World J Surg (2014) 1.50
Positional dyspnea and tracheal compression as indications for goiter resection. Arch Surg (2012) 1.46
Biliary strictures and masses: an expanded differential diagnosis. Abdom Imaging (2015) 1.41
American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid (2012) 1.36
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.32
Cystic parathyroid lesions: functional and nonfunctional parathyroid cysts. Arch Surg (2009) 1.30
Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab (2012) 1.24
RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab (2013) 1.22
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. Endocr Pract (2015) 1.22
The transcription factor interferon regulatory factor-1 mediates liver damage during ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol (2006) 1.21
A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer (2011) 1.21
Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol (2013) 1.19
IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene (2004) 1.19
The adrenal mass: correlation of histopathology with imaging. Ann Surg Oncol (2009) 1.16
American Thyroid Association statement on optimal surgical management of goiter. Thyroid (2014) 1.11
IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem (2004) 1.10
Hyperthyroidism after parathyroid exploration. Surgery (2005) 1.06
Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol (2011) 1.04
BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol (2012) 1.04
Parathyroid imaging. Radiol Clin North Am (2011) 1.04
The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist (2010) 1.03
Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res (2004) 1.02
A multi-institutional international study of risk factors for hematoma after thyroidectomy. Surgery (2013) 0.99
A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg (2014) 0.99
Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg Oncol (2002) 0.98
Thyroid cancers detected by imaging are not necessarily small or early stage. Thyroid (2013) 0.98
Tumor-to-tumor metastases to follicular variant of papillary thyroid carcinoma: histologic, immunohistochemical, and molecular studies of two unusual cases. Endocr Pathol (2009) 0.98
Imaging surveillance of differentiated thyroid cancer. Radiol Clin North Am (2011) 0.97
Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol (2014) 0.96
Repeat thyroid nodule fine-needle aspiration in patients with initial benign cytologic results. Am J Clin Pathol (2006) 0.95
Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. Thyroid (2012) 0.94
Thyroid carcinoma: the surgeon's perspective. Radiol Clin North Am (2011) 0.94
Localization of parathyroid adenomas by sonography and technetium tc 99m sestamibi single-photon emission computed tomography before minimally invasive parathyroidectomy: are both studies really needed? J Ultrasound Med (2009) 0.94
Postoperative surveillance of differentiated thyroid carcinoma: rationale, techniques, and controversies. Radiology (2008) 0.93
Cystic parathyroid adenoma: sonographic features and correlation with 99mTc-sestamibi SPECT findings. AJR Am J Roentgenol (2010) 0.93
18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med (2007) 0.93
Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells. Cancer Lett (2011) 0.92
Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery (2013) 0.91
Hepatic transplantation: postoperative complications. Abdom Imaging (2013) 0.91
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs (2007) 0.91
Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery (2013) 0.90
Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World J Surg (2006) 0.90
Summary statement: utility of molecular marker testing in thyroid cancer. Surgery (2010) 0.90
Tissue-engineered colon exhibits function in vivo. Surgery (2002) 0.89
Recurrent hyperparathyroidism secondary to parathyromatosis: clinical and imaging findings. J Ultrasound Med (2007) 0.87
Elevated serum parathormone level after "concise parathyroidectomy" for primary sporadic hyperparathyroidism. Surgery (2002) 0.87
Thyroid paragangliomas are locally aggressive. Thyroid (2011) 0.86
PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid (2014) 0.86
The inflammatory bowel disease live interinstitutional and interdisciplinary videoconference education (IBD LIVE) series. Inflamm Bowel Dis (2014) 0.86
Adrenal extracellular matrix scaffolds support adrenocortical cell proliferation and function in vitro. Tissue Eng Part A (2010) 0.85
Can a lightbulb sestamibi SPECT accurately predict single-gland disease in sporadic primary hyperparathyroidism? World J Surg (2008) 0.85
Does routine consultation of thyroid fine-needle aspiration cytology change surgical management? J Am Coll Surg (2007) 0.85
Allelic loss in parathyroid neoplasia can help characterize malignancy. Am J Surg Pathol (2005) 0.84
Recurrent hyperparathyroidism and forearm parathyromatosis after total parathyroidectomy. Surgery (2010) 0.83
Recent developments in predicting thyroid malignancy. Curr Opin Oncol (2009) 0.83
Sonography of intrathyroid parathyroid adenomas: are there distinctive features that allow for preoperative identification? Eur J Radiol (2012) 0.83
Imaging the spectrum of biliary tract disease. Radiol Clin North Am (2002) 0.82
Identification of a natural compound by cell-based screening that enhances interferon regulatory factor-1 activity and causes tumor suppression. Mol Cancer Ther (2011) 0.82
Outcome and prognostic factors after adrenalectomy for patients with distant adrenal metastasis. Ann Surg Oncol (2013) 0.82
Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg (2015) 0.81
Case-controlled comparison of video-assisted and conventional minimally invasive parathyroidectomy. Am Surg (2012) 0.81
The final intraoperative parathyroid hormone level: how low should it go? World J Surg (2014) 0.81